Updating results

341 results

Sort: Relevance | Date

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 1 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published October 2015

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

Summary of the evidence on zonisamide as monotherapy for children and young people with epilepsy to inform local NHS planning and decision-making

Evidence summary Published April 2013

Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

Summary of the evidence on linaclotide for irritable bowel syndrome (IBS) with constipation in adults to inform local NHS planning and decision-making

Evidence summary Published April 2013

Actinic keratosis: ingenol mebutate gel (ESNM14)

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

Summary of the evidence on racecadotril with oral rehydration for treating acute diarrhoea in children to inform local NHS planning and decision-making

Evidence summary Published March 2013

Acute diarrhoea in adults: racecadotril (ESNM11)

Summary of the evidence on racecadotril for treating acute diarrhoea in adults to inform local NHS planning and decision-making

Evidence summary Published March 2013

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

Evidence summary Published March 2016

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013

Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

Summary of the evidences on clonidine for attention deficit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published April 2013

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

Evidence summary Published February 2013

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

Summary of the evidence on docetaxel for treating hormone-sensitive metastatic prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2016

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Infantile haemangioma: topical timolol (ESUOM47)

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014